Euroclovir

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Euroclovir

Property Description
Active Ingredient Aciclovir (Acyclovir)
Pharmacological Class Antiviral (Purine Nucleoside Analog)
Origin Synthetic Compound
Common Forms Tablets, Cream, Ointment, Solution for Injection
Prescription Status Generally available by Prescription Only (Rx)

What Type of Medicine is Euroclovir?

Euroclovir is a medicinal product whose active component is Aciclovir, classified as a synthetic antiviral agent. Its composition establishes it as a purine nucleoside analog, a highly specific class of drugs developed to interfere with viral genetic processes. This classification positions Euroclovir as an essential, targeted agent for managing infections caused by specific viruses, notably those in the herpesvirus family. The drug's primary use is clinically recognized for its role in suppressing these acute viral outbreaks, which represents a typical use scenario.

Aciclovir's synthetic origin and precise function distinguish it fundamentally from antibiotics, which are only effective against bacteria. Aciclovir is used to reduce the growth and spread of certain viruses in the body, which characterizes its therapeutic action. While Euroclovir is the trade name used in specific markets, the active substance, Aciclovir, is widely recognized as a foundational medication in antiviral chemotherapy.


Composition and Available Forms

Euroclovir is a single-ingredient product whose only therapeutic substance is Aciclovir. The drug is provided in several dosage forms to accommodate various treatment requirements, distinguishing its utility based on the infection's location. These forms include preparations for systemic treatment, such as tablets and oral suspension, as well as local treatments like cream and ointment for topical application.

The availability of these forms facilitates different routes of administration, including oral, topical, and intravenous (for severe systemic cases). The existence of both topical and systemic preparations is a key differentiating feature of Aciclovir, ensuring that the antiviral agent can effectively address both localized skin manifestations and widespread internal infections.


General Purpose: Targeting Viral Replication

The primary purpose of Euroclovir is to suppress and manage viral infections by directly interfering with the virus’s ability to multiply. This action is rooted in the drug’s capacity for highly selective viral DNA synthesis inhibition. Once activated primarily within an infected cell, the drug causes chain termination, abruptly stopping the virus from copying its DNA. This targeted mechanism limits the spread and severity of the infection, which is the core benefit delivered by this specialized antiviral agent.

Regulatory References

  1. NIH MedlinePlus Drug Information on Acyclovir
  2. NIH Review of Aciclovir

What side effects are possible with Euroclovir?

Possible side effects and safety information

The safety profile of Euroclovir (Aciclovir) is established based on systematic classification of adverse reactions by frequency and the body system affected, as documented by official government health authorities.

Classification of Officially Documented Adverse Reactions

Adverse reactions are organized into System-Organ Classes, with key areas being the Gastrointestinal System, Nervous System, Skin and Subcutaneous Tissue, and the Renal and Urinary System.

Frequency Category Examples of Listed Effects
Common (Reported in ge1/100 patients) Headache, dizziness, nausea, vomiting, diarrhoea, abdominal pains, itching (pruritus), and rashes (including photosensitivity).
Uncommon Urticaria and accelerated diffuse hair loss.
Very Rare (Reported in <1/10,000 patients) Severe blood disorders (anemia, leucopenia, thrombocytopenia), agitation, confusion, tremor, convulsions, encephalopathy, acute renal failure, hepatitis, and severe skin reactions (e.g., Stevens-Johnson syndrome).

Safety Considerations for Specific Patient Populations

Official labeling identifies that older adults and patients with renal impairment carry an increased risk of developing neurological side effects such as confusion and agitation. Close monitoring is indicated for these groups due to the drug's elimination route. Furthermore, the label notes that the severe neurological adverse reactions documented are generally considered reversible upon discontinuation of the medicine.

General Regulatory Safety Notes

Safety information specifies that adequate hydration should be maintained during systemic treatment, particularly in older individuals or when high doses are administered. This is a critical factor for managing the risk of the drug precipitating in the kidneys. Additionally, co-administration with other medicines classified as nephrotoxic may increase the overall risk of renal dysfunction.

Overdose and Emergency Response

Suspected overdosage with Euroclovir requires that immediate medical attention be sought as stated in regulatory guidelines. Officially documented presentations of overdose typically involve effects on the central nervous system (CNS) and the renal system.

CNS manifestations include documented signs such as agitation, confusion, lethargy, and headache. In cases of severe toxicity, life-threatening outcomes such as seizures and coma have been reported. These severe neurological effects are associated primarily with intravenous administration or high drug concentrations resulting from reduced clearance.

The most serious physiological outcome documented in regulatory sources is acute renal failure, which results from the precipitation of the drug within the renal tubules. This risk is notably increased in geriatric patients and in individuals with pre-existing reduced kidney function.

Overdose management, as defined by regulatory bodies, focuses on symptomatic and supportive care. Patients must be subjected to close observation for developing signs of toxicity. Haemodialysis is an explicitly listed procedural management option for symptomatic overdosage, documented for its ability to enhance the removal of the drug from the system.

Therapeutic Uses of Euroclovir

What Euroclovir Treats: Main Uses and Benefits

This medication is commonly used to treat and manage conditions characterized by episodic or fluctuating symptom patterns that cause significant patient distress. It is utilized when supportive symptom management is appropriate across domains involving heightened responses. The medication is used for managing conditions that frequently present as cold sores, genital herpes episodes, and the acute symptoms of shingles.

It is applied in scenarios where additional management of discomfort is required, helping to address symptom clusters that may become intense or disruptive. This includes supporting the process of managing visible, disruptive lesions (blisters) and helping to improve comfort during episodes. For patients managing frequent symptomatic episodes, Euroclovir may assist with maintaining functional stability by helping to reduce the symptomatic burden associated with frequent recurrence.


Quick Fact: Focus on Symptom Management

Quick Fact: Focus on Symptom Management
Primary Focus Supports the management of acute pain and sensory symptoms (tingling, burning) that accompany viral outbreaks.
Key Benefit Supports the process of managing visible, disruptive lesions and helps improve day-to-day comfort during symptomatic periods.
Context Applied during phases where the patient experiences heightened discomfort from skin and nerve involvement.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Euroclovir — Official Regulatory Information

This section outlines the specific patient populations documented in regulatory labeling (such as the Summary of Product Characteristics) as either eligible or ineligible for treatment with Euroclovir.


Eligibility Scope

Classification Population/Condition Regulatory Statement
Contraindicated Hypersensitivity Known allergy to the active substance, euroclovir, or any of the excipients (e.g., history of anaphylaxis or angioedema).
Contraindicated End-Stage Renal Disease (ESRD) Prohibited for use in patients with End-Stage Renal Disease requiring dialysis.
Not Recommended Pediatric Population Use in children and adolescents under 18 years of age is not established and is therefore not recommended.
Not Recommended Severe Renal Impairment Not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min).
Restricted Use Pregnancy/Lactation Not recommended during pregnancy or breastfeeding, as per official label status. Use requires a formal risk-benefit assessment.
Special Consideration Older Adults (65 years) Use requires special consideration and potential dose adjustment due to age-related decline in kidney function.

Official Eligibility Summary

The primary restrictions for Euroclovir are based on two factors: the patient's immunological status and organ function. The medicine is contraindicated in patients with a history of severe allergic reactions (hypersensitivity) to its components and in patients with End-Stage Renal Disease (ESRD). Use is also not recommended in children under 18 and in patients with severe renal impairment or during pregnancy and lactation. These statements define the boundaries of the eligible patient population based strictly on governmental regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Euroclovir may interact with other medicines, primarily due to its route of elimination through the kidneys, specifically via active renal tubular secretion. Concomitant use with medicines that share or inhibit this pathway can alter the concentration of Euroclovir in the body.


Documented Interactions

Interaction Type Interacting Medicine/Category Practical Constraint/Observation
Inhibition of Elimination Probenecid Concomitant administration significantly increases Euroclovir plasma concentrations and half-life, and reduces renal clearance and urinary excretion.
Competition for Secretion Medicines that compete for active tubular secretion Co-administration may lead to elevated plasma levels of Euroclovir or the co-administered drug.
Increased Toxicity Risk Nephrotoxic medicinal products (e.g., NSAIDs) Increased risk or severity of nephrotoxicity (damage to the kidneys).

Clinical Context Notes

The co-administration of Euroclovir with other nephrotoxic agents requires caution, particularly in patients with pre-existing renal impairment or those who are volume-depleted. In such situations, the risk of deterioration in kidney function is increased. Healthcare providers must monitor for signs of worsening renal function when these combinations are necessary.

This information reflects the explicit constraints and mechanisms documented in official governmental regulatory labeling for the active substance.

Mechanism of Action

Selective Intracellular Activation and DNA Chain Termination

The action of Euroclovir begins with a two-step activation process highly specific to the infected cell. The inactive compound is preferentially converted into its active triphosphate form by the Viral Thymidine Kinase (vTK), an enzyme produced only by the target virus. This reliance confines the drug’s activation primarily to the environment of active viral multiplication.

The activated drug then targets the Viral DNA Polymerase enzyme. As a structurally similar but functionally flawed building block, it incorporates into the growing viral DNA strand, permanently disrupting the chain's structure. This obligatory DNA chain termination immediately and irreversibly stops the virus from synthesizing new genetic material, which results in the inhibition of viral DNA synthesis.

This mechanism is dependent on the virus being in an active state, as the necessary activating enzyme is not expressed when the virus is latent (dormant) in nerve tissue. This key constraint shows that the mechanism only functions during active viral replication and is non-functional against latent viral forms.

Dosage and Administration Information

How to Use Euroclovir

Euroclovir is administered via three distinct routes: oral (tablets or suspension), topical (cream or ointment), and intravenous (IV) solution for infusion. The route selected is determined by the standards for the specific condition and location of the infection. Oral forms may be taken with or without food for convenience of scheduling and must be initiated as early as possible—ideally at the first sign of symptoms—to adhere to the treatment protocol.

The medicine's usage patterns are defined concerning frequency and duration. Acute treatment for conditions such as herpes zoster (shingles) or acute herpes simplex episodes requires frequent use, typically five times daily (approximately every four hours while awake) for a standard course lasting between 5 and 10 days. For chronic suppressive use, the regimen is standardized to lower, less frequent doses, such as 400 mg taken twice daily; however, continuous therapy requires periodic reassessment.

Special Administration Conditions

Usage Context Instruction (Label-Based)
Intravenous Use Must be given as a slow infusion over at least one hour; requires concurrent adequate patient hydration to prevent potential issues.
Renal Function The standard dosage must be reduced in patients with renal impairment, with specific dose levels determined by creatinine clearance.
Missed Dose A missed oral dose should be taken immediately unless the time for the next scheduled dose is near, in which case the missed dose is skipped.

These instructions define the method of administration, including time-sensitive initiation and mandatory dose modifications for specific patient groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Euroclovir


Evidence for Use in Herpes Simplex Labialis (Cold Sores)

Euroclovir, containing the active substance Aciclovir, was studied for its use in managing symptoms related to cold sores, which are conditions characterized by fluctuating or episodic manifestations. Researchers examined its use in both oral tablet and topical cream forms through short-term Randomized Controlled Trials (RCTs) and meta-analyses. These trials included primarily immunocompetent adults and adolescents who had a history of recurrent cold sore outbreaks. The main focus of the research was on measured outcomes, such as the time until lesions healed or crusted over, and the duration of pain.

For oral formulations, the findings describe patterns observed in the studies where studies monitored measurements related to time until lesion healing in participants who started treatment very early. Research on longer-term oral regimens also explored the frequency of future outbreaks. In these studies, research describes patterns related to measurements of recurrence frequency over the observation period compared to placebo. The evidence is limited regarding its utility if the treatment initiation is delayed beyond the very early symptom stage.


Evidence for Use in Herpes Simplex Genitalis

Research examined Euroclovir's use for managing both first-episode and recurrent genital herpes, which is a condition associated with acute or disruptive episodes. The evidence base relies heavily on double-blind, placebo-controlled RCTs and systematic reviews. These studies was evaluated in adults with both initial and repeat episodes. Researchers examined outcomes such as the time needed for lesions to completely heal, the duration of viral shedding, and the prevention of new outbreaks during maintenance therapy.

In trials focused on acute episodes, findings indicate measurements related to time to lesion healing and duration of viral shedding compared to placebo. In suppressive therapy scenarios, studies described patterns related to the measurement of outbreak frequency over the observation period compared to recurrence patterns prior to treatment. Long-term effects are not fully established for continuous suppressive therapy extending beyond one to two years, meaning data are still emerging in this area.


Evidence for Use in Herpes Zoster (Shingles)

Euroclovir was studied for its use in managing shingles, a condition involving periods of heightened symptoms and nerve involvement. Study outcomes were monitored to capture outcomes related to systemic or functional imbalance, including the time until new lesions stopped forming, the rate of lesion healing, and the long-term assessment of postherpetic neuralgia (PHN)—a form of persistent nerve pain.

A key factor noted by researchers is that the pivotal trials focused on initiating treatment within 72 hours of the rash first appearing; consequently, the results apply only to the populations studied under this time constraint. Subgroup findings are uncertain regarding the full extent of pain prevention across all patient types, and comparative evidence is limited for certain outcomes when comparing Euroclovir against related treatments.

Key Studies & References

  1. Acyclovir: MedlinePlus Drug Information
  2. Acyclovir - StatPearls - NCBI Bookshelf (NIH)

Frequently Asked Questions (FAQ)

Common questions about Euroclovir (FAQ)

Q: What happens if I miss a dose of Euroclovir?

A: Official dosing guidelines state that if a dose is missed, it should be taken as soon as remembered. However, if it is already close to the time for the next scheduled dose, the missed dose is typically skipped, according to official dosing guidelines. This guideline applies to oral forms as well as topical cream and eye ointment preparations.


Q: What kind of studies have been conducted on Euroclovir?

A: The effectiveness of the medicine has been primarily established through clinical studies, including double-blind, placebo-controlled randomized trials. These studies, which are reviewed by regulatory bodies, focus on measuring specific outcomes for each condition the medicine is intended to treat.


Q: What happens if I accidentally take two Euroclovir tablets?

A: Official product information on overdose states that single, accidental intakes of large amounts have rarely resulted in toxic effects. Management in these situations is usually supportive, focusing on patient comfort and observation.


Q: Does Euroclovir interact with common pain relievers?

A: Regulatory sources indicate that no known clinical interaction has been found between the active substance (acyclovir) and non-prescription pain relievers like acetaminophen (paracetamol). Official guidance suggests informing your prescribing doctor about all other medicines you take, including over-the-counter products.


Q: Is it necessary to take Euroclovir with food?

A: Studies examined by regulatory bodies showed that taking the medicine with food did not affect how well it is absorbed by the body. Therefore, the oral forms of Euroclovir may be taken conveniently with or without a meal.


Q: Is Euroclovir available over the counter?

A: The active substance, Aciclovir, is primarily available in prescription-only forms, such as tablets, capsules, and oral suspensions. However, some lower-concentration topical cream forms are approved for purchase without a prescription in certain regions.


Q: Can Euroclovir cause problems with my kidneys?

A: Official warnings mention that kidney failure has been observed in some people using the medicine, especially when administered intravenously or in patients who already have kidney issues. Regulatory documents emphasize the importance of maintaining adequate hydration to help manage this risk.


Q: Is it common to feel tired while taking Euroclovir?

A: Tiredness or fatigue is not listed among the officially classified Common side effects. However, the label does list weakness, and user-reported information sometimes mentions feeling tired while taking the medicine.


Q: Are there any specific foods I should avoid while on Euroclovir?

A: Regulatory information indicates that there are no specific foods or dietary restrictions that are required to be avoided while using this medicine. Oral forms can be taken with or without food.


Q: Is Euroclovir safe to take if I am pregnant?

A: Official product information states that animal studies did not show harm to the fetus. However, studies in pregnant women are not sufficient to definitively determine the risk. Official sources indicate that the medicine is only used during pregnancy when a formal risk-benefit assessment determines the potential health benefit outweighs the potential risks.


Q: How long can a person usually stay on Euroclovir?

A: For continuous suppressive therapy of recurrent conditions, regulatory guidance allows for use for up to 12 months, after which re-evaluation is recommended. Official research has observed the use of the medicine for up to 10 years in some patient groups.


Q: Can I drive or operate machinery after taking Euroclovir?

A: Official patient information notes that the medicine may cause effects such as dizziness or drowsiness in some people. Patients are advised to be cautious when driving or operating machinery until they understand how the medicine affects them.


Q: Is Euroclovir affected by alcohol consumption?

A: There is no direct restriction or known contraindication between this medicine and alcohol consumption listed in official documents. Official product information notes that excessive alcohol intake can lead to dehydration, which is a factor associated with an increased risk of side effects related to kidney function.


Q: Does Euroclovir have a black box warning in the US?

A: The US Food and Drug Administration (FDA) label for the oral forms of this medicine does not contain a specific black box warning. The official Warnings section does, however, highlight risks, including renal failure.


Q: Is Euroclovir used for treating cold sores?

A: Yes, official indications confirm that the medicine is approved for the treatment of specific herpes simplex virus infections, including mucocutaneous infections which cover common cold sores (Herpes Simplex Labialis).


Q: Are there any long-term health risks associated with Euroclovir?

A: Official product information recommends re-evaluating the need for chronic suppressive use after 12 months. This recommendation exists because long-term effects beyond this period are not fully established in all regulatory data.


Q: Does Euroclovir affect birth control pills?

A: Official drug interaction checks indicate that no known clinical interaction has been established between the active substance (acyclovir) and common oral contraceptives (birth control pills).


Q: Can Euroclovir be taken with a multivitamin?

A: Specific contraindications with standard multivitamins are generally not listed in official sources. Official guidance recommends that patients inform their healthcare provider about all medicines, vitamins, or supplements they take.


Q: What if I have an allergic reaction to Euroclovir?

A: Official adverse reaction reports include severe allergic responses such as anaphylaxis (a sudden, severe reaction) and angioedema (swelling). These symptoms, which include severe allergic responses, are recognized as serious and require prompt medical review.


Q: Does Euroclovir interact with herbal supplements like St. John's Wort?

A: Official regulatory information does not contain specific interaction testing for the medicine with most herbal remedies, including St. John’s Wort. Therefore, there is insufficient information to determine if these combinations are safe.


Q: Is Euroclovir considered a first-line treatment for its primary indication?

A: Official treatment recommendations, such as those from the Centers for Disease Control and Prevention (CDC), list the active substance (Acyclovir) alongside other antiviral medications as a recommended option for initial episodes of genital herpes.


Q: What is the difference between Euroclovir capsules and tablets?

A: The product is available in several systemic forms, including tablets, capsules, and oral suspension. Official labels confirm that the capsule and tablet forms have been shown to be bioequivalent, meaning they are expected to have the same effect in the body.


Q: What is the half-life of Euroclovir?

A: Pharmacokinetic data from official sources indicate that the mean plasma elimination half-life of the active substance in adults with normal kidney function is approximately 2.5 to 3.3 hours.


Q: Does taking Euroclovir affect liver function tests?

A: Regulatory documents report that elevated liver function tests and hepatitis (liver inflammation) have been observed as adverse reactions during clinical practice.


Q: What are the signs of Euroclovir toxicity?

A: Official information regarding overdosage and severe adverse reactions mentions signs of toxicity such as acute kidney failure and neurological issues. These neurological signs can include confusion, hallucinations, and tremors.


Q: Does Euroclovir cause changes in mood or behavior?

A: Official reports indicate behavioral changes, including aggression, agitation, confusion, hallucinations, and psychosis, have been observed as adverse reactions, particularly in older adults or those with impaired kidney function.


Q: What is the difference in side effects for children versus adults taking Euroclovir?

A: The safety of the oral tablet form has not been established in children younger than 2 years old. Regulatory labels specifically note that older adults are at an increased risk of neurological side effects compared to younger adults.


Q: Does Euroclovir have to be taken at the exact same time every day?

A: Official dosing guidelines recommend spacing doses evenly throughout the day, such as taking the oral tablet approximately every four hours while awake. Maintaining consistent intervals is considered key to drug management.


Q: Is there a generic version of Euroclovir available?

A: Yes, the active substance in Euroclovir is widely available as a generic drug known as Acyclovir, which is confirmed in official drug information sources.

How should Euroclovir be stored and disposed of?

Storage and Disposal of Euroclovir (Acyclovir Tablets)

Euroclovir tablets must be stored under specific conditions to maintain their stability, as defined by regulatory documents. The medicine should be stored at Controlled Room Temperature, typically between 15°C and 25°C (59°F and 77°F). It is required that the product be kept in a tight, light-resistant container and protected from both light and moisture. The tablets must not be refrigerated or frozen.

Handling and Safety

For safety, the medicine must be stored out of the sight and reach of children at all times.

Disposal

Unused or expired Euroclovir must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard the medicine into wastewater or household trash; return unwanted medicines to a pharmacy or drug take-back location for proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Euroclovir found in:

A-Z Index: